As­traZeneca, Io­n­is un­veil full PhI­II da­ta for 'mega brand' AT­TR drug

As­traZeneca and Io­n­is fleshed out a Phase III win for eplon­ter­sen Mon­day morn­ing at this year’s Amer­i­can Acad­e­my of Neu­rol­o­gy meet­ing, il­lus­trat­ing why the pair is so con­fi­dent in its po­ten­tial suc­cess.

Eplon­ter­sen all but halt­ed pa­tients’ dis­ease pro­gres­sion af­ter 66 weeks in a fa­tal neu­rode­gen­er­a­tive dis­ease known as hered­i­tary transthyretin-me­di­at­ed amy­loid polyneu­ropa­thy (AT­TRv-PN). In a com­pos­ite score of polyneu­ropa­thy clin­i­cal mea­sure­ments like mus­cle strength and blood pres­sure, pa­tients tak­ing eplon­ter­sen record­ed a 0.28-point av­er­age in­crease from base­line com­pared to a 25.06-point av­er­age in­crease in the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER